Literature DB >> 15015774

Drug-induced apoptosis by a matrix metalloproteinase inhibitor, SI-27 on human malignant glioma cell lines; in vitro study.

Ryuzaburo Kanazawa1, Daizo Yoshida, Hiroshi Takahashi, Yuichi Sugisaki, Satoru Suzuki, Akira Teramoto.   

Abstract

Matrix metalloproteinase (MMP) plays important roles in cell invasion and tumor angiogenesis. SI-27, an anti-MMP agent, has already been shown to possess both in vitro anti-invasive and anti-angiogenic properties against malignant gliomas in non-cytotoxic dose concentrations. However, to the best of our knowledge, the molecular mechanism mediating the cytotoxic action by this agent and the molecular mechanism in the cytotoxic action against malignant glioma cell have not yet been clarified. Therefore, we assessed the effect in the cytotoxic dose concentrations to investigate whether this cytotoxic action is related to apoptosis in this study. The effect on human glioma cell lines (U87MG, U251MG, and U373MG) was examined by transmission electron microscope, agarose gel electrophoresis with the DNA fragmentation, flow cytometry with FITC-conjugated Annexin V, and detection of caspase activity. Drug-induced apoptosis was observed in the cytotoxic dose. The result indicated that the cytotoxity of SI-27 might be related to the drug-induced apoptosis mediated by caspase.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15015774     DOI: 10.1023/b:neon.0000013491.78909.43

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  34 in total

Review 1.  The regulation of neovascularization of matrix metalloproteinases and their inhibitors.

Authors:  M A Moses
Journal:  Stem Cells       Date:  1997       Impact factor: 6.277

2.  Requirement of caspase and p38MAPK activation in zinc-induced apoptosis in human leukemia HL-60 cells.

Authors:  Masuo Kondoh; Emi Tasaki; Saeko Araragi; Masufumi Takiguchi; Minoru Higashimoto; Yoshiteru Watanabe; Masao Sato
Journal:  Eur J Biochem       Date:  2002-12

3.  Reduction of in vivo tumor growth by MMI-166, a selective matrix metalloproteinase inhibitor, through inhibition of tumor angiogenesis in squamous cell carcinoma cell lines of head and neck.

Authors:  Hideaki Katori; Yuh Baba; Yukari Imagawa; Goshi Nishimura; Yuumi Kagesato; Emi Takagi; Akiko Ishii; Shunsuke Yanoma; Ryuji Maekawa; Takayuki Yoshioka; Yoji Nagashima; Yasumasa Kato; Mamoru Tsukuda
Journal:  Cancer Lett       Date:  2002-04-25       Impact factor: 8.679

4.  Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials.

Authors:  D R Shalinsky; J Brekken; H Zou; C D McDermott; P Forsyth; D Edwards; S Margosiak; S Bender; G Truitt; A Wood; N M Varki; K Appelt
Journal:  Ann N Y Acad Sci       Date:  1999-06-30       Impact factor: 5.691

5.  The matrix metalloproteinase inhibitor batimastat inhibits angiogenesis in liver metastases of B16F1 melanoma cells.

Authors:  S Wylie; I C MacDonald; H J Varghese; E E Schmidt; V L Morris; A C Groom; A F Chambers
Journal:  Clin Exp Metastasis       Date:  1999-03       Impact factor: 5.150

6.  Effect of synthetic matrix-metalloproteinase inhibitors on invasive capacity and proliferation of human malignant gliomas in vitro.

Authors:  J C Tonn; S Kerkau; A Hanke; H Bouterfa; J G Mueller; S Wagner; G H Vince; K Roosen
Journal:  Int J Cancer       Date:  1999-03-01       Impact factor: 7.396

7.  Fas-mediated apoptosis in Ewing's sarcoma cell lines by metalloproteinase inhibitors.

Authors:  N Mitsiades; V Poulaki; A Leone; M Tsokos
Journal:  J Natl Cancer Inst       Date:  1999-10-06       Impact factor: 13.506

8.  Matrix metalloproteinases and tissue inhibitors of metalloproteinases in human gliomas.

Authors:  A Nakano; E Tani; K Miyazaki; Y Yamamoto; J Furuyama
Journal:  J Neurosurg       Date:  1995-08       Impact factor: 5.115

9.  Phase II study of marimastat (BB-2516) in malignant melanoma: a clinical and tumor biopsy study of the National Cancer Institute of Canada Clinical Trials Group.

Authors:  Ian Quirt; Audley Bodurth; Reinhard Lohmann; James Rusthoven; Karl Belanger; Vincent Young; Nancy Wainman; William Stewar; Elizabeth Eisenhauer
Journal:  Invest New Drugs       Date:  2002-11       Impact factor: 3.850

10.  Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas.

Authors:  P A Forsyth; H Wong; T D Laing; N B Rewcastle; D G Morris; H Muzik; K J Leco; R N Johnston; P M Brasher; G Sutherland; D R Edwards
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

View more
  1 in total

1.  The relationship between the expression of tumor matrix-metalloproteinase and the characteristics of magnetic resonance imaging of human gliomas.

Authors:  Lihua Liu; Ming Zhang; Yuan Wang; Min Li
Journal:  J Biomed Res       Date:  2010-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.